Morphine is the oldest worldwide well-known opioid agonist used for pain treatment in clinic, and its illicit use is often associated with adverse pregnancy outcomes in humans. Because of recent dramatic increases in nonmedicinal morphine abuse, one emerging issue is the further revelation of the dark side of illicit opioid uses, particularly in early pregnancy events. In this respect, we have demonstrated that opioid signaling is functionally operative during preimplantation embryo development in mice. However, the pathophysiological significance of the opioid system on uterine functions at peri-implantation remained elusive. In the present study, we demonstrated that opioid receptors were spatiotemporally expressed in the uterus during the peri-implantation period. Employing a pharmacological approach combined with embryo transfer experiments, we further observed that although systemic morphine treatment exerts no apparent adverse influence on preimplantation ovarian secretion of progesterone and estrogen, this aberrant activation of opioid signaling by morphine induces impaired luminal epithelial differentiation, decreased stromal cell proliferation, and poor angiogenesis, and thus hampers uterine receptivity and embryo implantation. These novel findings add a new line of evidence to better understand the causes for obvious adverse effects of opioid abuse on pregnancy success in women.
INTRODUCTION
Successful implantation requires synchronization between blastocysts achieving implantation competency and uteri entering a receptive state [1] , whereas a disruption of this process contributes to approximately 70% of early pregnancy loss [2] [3] [4] . A wide range of regulatory molecules, including ovarian steroid hormones, cytokines, growth factors, lipid metabolites, transcription factors, and developmental genes, have been shown to be involved in regulating the dynamic duration of embryo implantation [1] . However, this precisely regulated embryo-uterine dialog can be hampered by various external factors and conditions, such as environmental exposure, maternal stress status, and particularly drug abuse. For example, previous studies have demonstrated that aberrant cannabinoid signaling exhibits detrimental effects on early pregnancy events, including the derailment of the normal preimplantation development of early embryos and their timely oviductal transport, and the disruption of blastocyst implantation competency and uterine receptivity, and thus embryo implantation [5] [6] [7] [8] [9] [10] . Moreover, the illicit use of opioids during pregnancy is often associated with adverse pregnancy outcomes, such as poor fetal growth, preterm delivery, and fetal death [11] [12] [13] [14] [15] [16] [17] . In this respect, our recent study revealed that although opioid signaling is functionally operative during preimplantation embryo development, opioid signaling aberrantly activated by morphine can impair the normal preimplantation embryo development remarkably via the inhibition of intracellular calcium mobilization [18] . However, the pathophysiological significance of the opioid system on uterine functions at peri-implantation has remained largely unexplored.
The endogenous opioid system consists of a family of structurally related small peptides-endorphins, enkephalins, and dynorphins-as ligands, which act through three major opioid receptor subtypes, including l opioid receptor (MOR), d opioid receptor (DOR), and j opioid receptor (KOR) [19] . In addition, there are several plant-derived and synthetic compounds that can also function through opioid receptors, known as exogenous opioids. Among them, morphine is the oldest worldwide well-known opioid agonist that has been used for the treatment of severe acute and chronic pain [20] . Because morphine is the one of the most widely abused prescription drugs, behind only marijuana in Western countries [21] [22] [23] [24] , and that morphine addiction has been frequently observed in consumers of either medicinal or illicit use, it is meaningful to explore the potential consequence of morphine exposure on uterine receptivity and implantation during early pregnancy.
In the present study, we demonstrated that opioid receptors were spatiotemporally expressed in the uterus during the periimplantation period. Employing a pharmacological approach combined with embryo transfer experiments, we further observed although systemic morphine treatment exerts no apparent adverse influences on preimplantation ovarian secretion of progesterone and estrogen, this aberrant activation of opioid signaling by morphine induces impaired luminal epithelial differentiation, decreased stromal cell proliferation, and poor angiogenesis, thus hampering uterine receptivity and embryo implantation. These findings help to better understand the causes for obvious adverse effects of opioid abuse on pregnancy success in women.
MATERIALS AND METHODS

Animals and Treatments
Mice were housed in the Institutional Animal Care Facility of the Institute of Zoology according to institutional guidelines for laboratory animals. C57BL/ 6 female mice (age 8 wk) were purchased from the Vital River Laboratory Animal Technology Co. Ltd. Oprm
, and Oprd À/À mouse models were purchased from the Jackson Laboratory. Female mice that had a vaginal plug on the morning after being caged with fertile or vasectomized males were considered as being on Day 1 of pregnancy or pseudopregnancy, respectively. To examine the effect of morphine on blastocyst implantation in vivo, pregnant or pseudopregnant mice received intraperitoneal injections of morphine (50 mg/ kg body weight [BW] ; Sinopharm Group Co. Ltd.) and/or naloxone (1 mg/kg BW; Tocris Cookson Ltd.) on Days 3-4 [25] [26] [27] . To prevent rapid turnover of morphine by the liver metabolic enzyme UGT2B7 [28] [29] [30] , mice receiving the morphine were preinjected intraperitoneally with celastrol (5 mg/kg BW), an effective UGT2B7 inhibitor. Blastocysts recovered from pregnant mice were transferred into the pseudopregnant females on the morning of Day 4, as previously described [9, 31] . Mice injected with sterile saline served as the control. Implantation sites were visualized by the blue dye method on the morning of Day 5. Uteri devoid of signs of blue reaction were flushed to recover unimplanted embryos. To analyze the cell proliferation status, mice were intraperitoneally injected with bromodeoxyuridine (BrdU) solution (0.3 mg/10 g BW; Sigma) 2 h before killing. Mouse blood samples were collected on the morning of Day 4, and serum progesterone and 17b-estradiol levels were measured by radioimmunoassay.
Quantitative Real-Time PCR Total RNA isolated from uteri by TRIzol (Invitrogen) was used to synthesize cDNA. The expression levels of different genes were validated by quantitative RT-PCR analysis using the ABI 7500 sequence detector system according to the manufacturer's instructions (Applied Biosystems). All primers for real-time PCR are listed in Supplemental Table S1 (Supplemental Data are available online at www.biolreprod.org). Assays were performed at least three times with each in duplicate.
In Situ Hybridization
In situ hybridization with isotopes was performed on cryosections as described previously [32] . Briefly, frozen sections (10 lm) were hybridized with the mouse-specific 35 S-labeled cRNA probes Oprm, Oprd, Oprk, Ltf, and Lif, respectively. Sections hybridized with the sense probes served as negative controls and showed no positive signal.
Immunostaining
To localize the opioid receptors in peri-implantation uteri, the cryosections fixed in 4% paraformaldehyde in 0.1 M PBS (pH 7.4) were used for immunofluorescent staining. Antibodies specific to MOR (Thermo Scientific), DOR (Santa Cruz Biotechnology), and KOR (Santa Cruz Biotechnology) were used. Hoechst 33342 (Sigma) was used for nuclear staining. All sections were incubated with primary antibodies at 48C overnight, followed by incubation with secondary antibody conjugated with Cy3 dyes (Jackson ImmunoResearch Laboratories) at room temperature for 1 h. Immunofluorescent images were captured in a Zeiss LSM 710 confocal scanning laser microscope. For immunohistochemical analysis in 10% neutral buffered formalin-fixed, paraffin-embedded sections, antibodies specific to P450SCC (Santa Cruz Biotechnology), 3b-HSD (Santa Cruz Biotechnology), ERa (Dako), PR (Dako), Ki-67 (Epitomics), BrdU (Abcam), VEGF (Abcam), Hand2 (Abcam), MUC1 (Abcam), PECAM1 (BD), or p-ERa (Ser118; Santa Cruz Biotechnology) were used. High-temperature heating was used for antigen retrieval. A Histostain-SP Kit (Zhongshan Golden Bridge Biotechnology) was applied to visualize the antigen.
Western Blot Analysis
Protein extraction and Western blotting were performed as previously described [1] . Specific antibodies to VEGF (Abcam), Hif1a (Abcam), and bactin (Sigma) were used. b-Actin served as a loading control.
Primary Uterine Stromal Cell Culture
Murine primary uterine endometrial stromal cells were isolated and cultured as previously described, with some modifications [33] . The uterus of pseudopregnant mouse on Day 4 was cut into small pieces (3-4 mm). Those tissue pieces were first digested in Hanks balanced salt solution containing 6 mg/ml dispase (Gibco) and 25 mg/ml trypsin (Sigma), and then incubated in Hanks balanced salt solution containing 0.5 mg/ml collagenase (Gibco). The digested cells were passed through a 70-lm filter to obtain the stromal cells. Cells were plated at 5 3 10 5 cells per 60-mm dish or the corresponding number according to dish area, cultured with phenol red-free Dulbecco modified Eagle medium and Ham F-12 nutrient mixture (1:1 DMEM:F12; Gibco) containing 10% charcoal-stripped fetal bovine serum (Biological Industries) and antibiotics. Two hours later, the medium was replaced with fresh medium with respective reagents.
Statistical Analysis
All data were analyzed by the SPSS 11.5 program and are presented as mean 6 SEM. Comparisons between groups were tested by the independentsamples t-test. Values were considered significantly different if P 0.05.
RESULTS
Opioid Receptors Are Spatiotemporally Expressed in the Mouse Peri-implantation Uterus
To explore the pathophysiological significance of opioid signaling in early pregnancy, we first analyzed the uterine expression profile of l opioid receptor (Oprm), j opioid receptor (Oprk), and d opioid receptor (Oprd) during early pregnancy by in situ hybridization experiments. As shown in Figure 1A , Oprm mRNA was prominently detected in luminal and glandular epithelium on Day 1 of pregnancy, and can be further detected at low levels in the stroma on Day 4. With the initiation and progression of implantation and decidualization, Oprm was expressed in decidualizing stromal cells on Days 5-6 ( Fig. 1A) . Moreover, whereas Oprd mRNA was expressed at low levels in uterine epithelium and stoma on Days 1-4, an increased expression level was observed in the underlying stroma surrounding the implanting blastocyst on Day 5, which then further expanded to the decidualizing zone on Day 6 (Fig.  1A) . With respect to Oprk receptor, we noted a high level of Oprk mRNAs in Day 1 uterine epithelium, whereas its level remained low in both epithelial and stromal cells on Day 4 and beyond (Fig. 1A) . Subsequent immunofluorescence staining analysis further confirmed the expression of opioid receptors MOR, DOR, and KOR in the luminal epithelial layer on Day 1 of pregnancy, and in both epithelial and stromal cells in the receptive uterus on Day 4 (Fig. 1B) . These spatiotemporal expressions of opioid receptors indicated that opioid signaling could be a potential player regulating uterine functions during early pregnancy, which provoked us to further analyze whether an aberrant activation of opioid signaling by morphine would interfere with normal embryo implantation.
Systemic Morphine Treatment Hampers Normal Blastocyst Implantation in Mice
To test our speculation, pregnant mice were treated with morphine on Days 3-4 of pregnancy, and implantation status was examined on Day 5 by the blue dye method. As shown in Figure 2 , A and B, although all tested mice that received saline treatment exhibited normal implantation showing visible blue bands, only three of seven (less than 40%) morphine-treated females showed a blue reaction, with a significantly reduced number of implantation sites. Morphologically normal blastocysts, frequently encased in the zona pellucida, could be recovered in drug-treated females without signs of a blue reaction (Fig. 2C) . However, this inhibitory effect of morphine on implantation events can be largely reversed by cotreatment with the morphine antagonist naloxone (Fig. 2, A and B) . Observations of impaired implantation process, but not complete implantation failure, upon morphine challenge could be due to a quick turnover of morphine in the liver by the degrading enzyme UGT2B7 in vivo. We then cotreated the pregnant females with morphine and celastrol, a UGT2B7 selective inhibitor, and observed that this prevention of rapid TANG ET AL. systemic morphine degradation resulted in implantation defects that were more severe. Only two of nine mice receiving cotreatments of morphine and celastrol showed a blue reaction, and the number of implantation sites was sharply decreased, even in comparison with the morphine only-treated females (Fig. 2, A and B) . These results suggested that a pharmacological activation of opioid signaling is detrimental to normal blastocyst implantation in mice. However, considering the fact that the preimplantation embryo is a target of opioid signaling [18] , it remained elusive regarding the respective embryonic versus uterine contribution to this obvious defective implantation from systemic morphine treatment.
To address this issue, we next performed reciprocal embryo transfer experiments. As illustrated in Figure 2 , D and E, only less than 20% of normal Day 4 blastocysts showed implantation on Day 5 when they were transferred into the pseudopregnant females receiving morphine treatment on the morning of Day 4, whereas about 60% of blastocysts showed implantation after transfer into control mice. Moreover, none of the transferred normal blastocysts showed signs of implantation in morphine and celastrol cotreated recipients (Fig. 2, D and E) , and most of the blastocysts can be recovered by flushing the uterine horns (Fig. 2F) . In contrast, normal implantation occurred when the blastocysts recovered from morphinetreated pregnant females were transferred into the normal Day 4 pseudopregnant recipients. We observed that 12 of 16 blastocysts preexposed to morphine treatment showed implantation 24 h after being transferred into normal recipients (n ¼ 2). These results clearly point toward the detrimental effects of systemic morphine treatment on uterine functions during early pregnancy.
Further examination of three opioid receptors' expression levels after morphine exposure confirmed the direct influence on uteri, because both the mRNA and protein levels of these genes were significantly downregulated upon morphine treatment (Supplemental Fig. S1 ), which is a common feedback regulatory mechanism of ligand-activated GPCR [34, 35] . Because all three receptors were expressed in the periimplantation uteri, we then used the genetic knockout mouse model to ascertain the functional receptor during the implantation stage. As illustrated in Table 1 , although the adverse effect of morphine exposure on implantation was completely abolished in Oprm À/À females, this adverse effect still existed in Oprk À/À /Oprd À/À double-mutant mice. These results indicated that the OPRM (l) receptor is the main functional receptor subtype in response to morphine during implantation in mice. It is conceivable that a tightly regulated endogenous opioid ligand-receptor signaling is essential for normal embryo implantation in mice. In this respect, our unpublished data indeed attest to a coordinated expression of opioid precursor processing enzymes and dynamic levels of endogenous ligands in the peri-implantation uterus.
Systemic Morphine Treatment Derails Normal Uterine Receptivity
Because uterine function at peri-implantation is under the profound influence of the ovarian steroid hormones progesterone and estrogen, and because long-term morphine treatment can adversely affect gonadal steroidogenesis [36] [37] [38] , to further ascertain whether implantation failure by morphine challenge results from intrinsic and/or extrinsic uterine defects, we next examined the circulating levels of progesterone and 17b-estradiol in response to morphine treatment. As shown in Figure 3A , the serum levels of progesterone and 17b-estradiol were comparable between the saline-and morphine-treated females on Day 4 of pregnancy. This finding was consistent with normal ovarian localization and expression of key steroid biosynthetic enzymes-cytochrome P450 cholesterol sidechain cleavage enzyme (P450SCC) and 3b-hydroxysteroid 
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dehydrogenase (3b-HSD)-in both groups (Fig. 3B) . These results suggested that short-term morphine treatment exerts no apparently adverse effects on ovarian progesterone and estrogen biosynthesis. We next explored the consequence of morphine exposure on uterine receptivity attainment.
It has been well established in mice that uterine receptivity can be characterized by several key marker genes, such as lactoferrin (Ltf), mucin 1 (Muc-1), leukemia inhibitory factor (Lif), COUP transcription factor II (Coputf-II, also known as Nr2f2), heart and neural crest derivatives expressed transcript 2 (Hand2), homeobox A-10 (Hoxa-10), and others [39] [40] [41] [42] . Employing quantitative RT-PCR analysis combined with in situ hybridization and immunohistochemical staining, we observed a significantly elevated expression of Muc-1 and 
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Ltf, the well-characterized estrogen-regulated genes [43, 44] , in the uterine epithelial layer in morphine-treated females on Day 4 of pregnancy (Fig. 4 , A-C), whereas Lif mRNA expression was dramatically reduced in Day 4 uterine glandular epithelium in drug-treated females (Fig. 4, A and B) . Moreover, the expression of progesterone-responsive genes Hand2, Hoxa-10, and Coup-TFII was also remarkably reduced in uterine stroma in females receiving morphine treatment (Fig. 4A) , reflecting an impaired stromal capacity to respond to progesterone upon morphine challenge. Then we examined the expression of steroid hormone receptors ERa and PR in the uterus after morphine exposure. Although the total level of ERa was comparable in morphine-treated and control groups, phosphorylated ERa was largely increased in the epithelium in response to morphine treatment (Fig. 4D) . The progesterone receptor PR showed normal expression even after morphine exposure. However, the PR-regulated gene Hand2 was decreased significantly (Fig. 4D ). This increased phosphorylated ERa expression in luminal epithelium and decreased Hand2 expression in the stroma reinforced a defective uterine receptivity upon morphine exposure. Nonetheless, the results clearly indicated impaired uterine receptivity by systemic morphine exposure.
Morphine Attenuates Uterine Stromal Proliferation and Angiogenesis, Resulting in Disrupted Uterine Receptivity
In the receptive phase of the uterus, while luminal epithelial cells undergo differentiation, the stromal cells underneath initiate extensive proliferation and differentiation under the influence of preimplantation estrogen and progesterone priming [1] . Observations of largely reduced progesteroneresponsive gene expressions in morphine-treated uterus led us to speculate that the stromal proliferation would be hampered by systemic morphine treatment. Indeed, both Ki-67 immunostaining and BrdU incorporation analysis revealed a remarkably attenuated stromal cell proliferation (Fig. 5A) , reinforcing the notion of impaired progesterone-directed uterine functions upon morphine exposure.
Because increased vascular permeability and subsequent angiogenesis, which is dynamically regulated by progesterone and estrogen [45] , are hallmark events of implantation, we also compared the blood vessel density in the uterine stromal bed by platelet endothelial cell adhesion molecule (PECAM1, also known as CD31) staining in mice receiving saline versus morphine treatment. As shown in Figure 5 , B and C, we observed a progressive vessel regression in morphine-treated uteri. This decreased density of blood vessels in uterine endometrium was well correlated with reduced mRNA and protein expressions of hypoxia-inducible factor 1a (Hif1a) and VEGF (Fig. 5, D-F) . To further confirm the inhibitory effect of morphine on uterine expression of Hif1a and Vegf, we explored the in vitro-cultured stroma cell model. As shown in Figure 5G , both Hifa and Vegf were downregulated in stroma cells upon morphine treatment. These findings were consistent with the previous finding that the Hif1a-VEGF signaling cascade is essential for normal uterine angiogenesis in mice [46, 47] , further shedding light on the molecular basis for morphine's detrimental effects on uterine receptivity. Moreover, the progesterone-upregulated Hand2 expression was ablated by morphine treatment (Fig. 5H) , suggesting a hampered progesterone activity in uterine stromal cells after morphine exposure, as that observed in the in vivo-treated mice.
DISCUSSION
Previous studies have ascribed critical roles to the opioid system in regulating pain, stress, and addiction [48, 49] . Because the use of prescription opioids to relieve severe pain has soared in the past two decades, and a dramatic increase in prescription opioid abuse was recently reported [21] [22] [23] [24] , one emerging issue is the revelation of the causes accounting for the dark side of illicit use of opioids, particularly in pregnancy events. Our recent studies and others have reported the expression and function of opioid receptors in sperm, preimplantation embryos, and placental tissues [18, [50] [51] [52] . In the present study, we further demonstrated that the opioid system is functionally operative during uterine receptivity attainment and embryo implantation. A systemic morphine exposure induced aberrant uterine receptivity marker gene expression, accompanied by remarkably reduced endometrial stromal proliferation and an impaired angiogenesis, eventually leading to implantation failure.
Previous studies have demonstrated that the duration of uterine receptivity is primarily settled by ovarian progesterone and estrogen [1, 53] . For example, in mice, although preovulatory estrogen provokes massive luminal epithelial proliferation, increasing levels of progesterone from the newly formed corpus luteum stimulate uterine stromal proliferation on Day 3. With the priming of progesterone, the preimplantation secretion of estrogen on Day 4 facilitates endometrial stromal proliferation, whereas the luminal epithelium gradually undergoes differentiation, and the uterus enters into the receptive phase for blastocyst implantation. Observations of relatively intensive expression of all opioid receptor subtypes in Day 1 luminal epithelium suggest that opioid signaling may involve directing uterine activities during the journey of postcopulation sperm-egg dating under the influence of estrogen surge. Under the dominance of progesterone, we observed an enhanced opioid receptor expression in the stroma prior to implantation and later in the decidualizing zone after attachment reaction, suggesting that opioid signaling is operative quite early during uterine preparation for implantation. This is further verified in the present study showing that opioid signaling aberrantly enhanced by morphine significantly disrupts the implantation process. It is also reasonable to observe that a blockage of morphine turnover rate by the selective degrading enzyme inhibitor induces more severe implantation defects. A similar MORPHINE DERAILS UTERINE RECEPTIVITY phenomenon has also been previously observed in testing the adverse effects of marijuana exposure on early pregnancy events [7, 54] .
Our recent study has demonstrated that preimplantation embryos spanning from zygote to blastocyst express all of the opioid receptor subtypes, and opioid signaling aberrantly activated by morphine can derail the normal preimplantation embryo development remarkably via the inhibition of intracellular calcium mobilization [18] , suggesting that the preimplantation embryo is a target of the opioid system during early pregnancy. This is further confirmed in the present study showing the recovery of zona pellucida-encased blastocysts in morphine-treated females even on Day 5 of pregnancy, suggesting there is a deferral of preimplantation embryo development into blastocyst and the subsequent process of zona pellucida dissolution. However, it also can be argued that derailed uterine function is insufficient to support blastocyst development and activation for implantation. In this respect, our reciprocal embryo transfer experiments provided direct evidence that systemic morphine treatment can no doubt disrupt normal uterine receptivity. This adverse effect of morphine on uterine function is an intrinsic uterine defect, because the ovarian progesterone and estrogen levels are unaltered after a 2-day acute morphine exposure. This observation is certainly a plus to the previous findings that long-term morphine treatment can exert an adverse influence on the hypothalamic-pituitary-gonadal axis [36] [37] [38] .
In searching for the causes of defective uterine functions upon morphine treatment, we observed with interest that LIF, the first well-characterized cytokine indispensable to normal blastocyst implantation, is largely downregulated in the glandular epithelium by morphine treatment in mice [55] . However, the potential underlying mechanism warrants further investigation. Moreover, we demonstrated that morphine exposure induces abnormal progesterone-regulated uterine activities, including downregulation of progesterone-responsive gene expression, attenuated stromal cell proliferation, and progressive blood vessel regression. This defective uterine transformation, particularly the impaired angiogenesis prior to embryo attachment, is associated with a significant reduction of Hif1a and VEGF expression in response to morphine exposure. In fact, there is evidence that morphine can inhibit Hif1a and VEGF expression, and thus angiogenesis, in various pathophysiological conditions [56, 57] . However, it should not be excluded that morphine may exert adverse effects directly on endothelial cells in the uterus, as previously reported [58, 59] .
In conclusion, in the current study we provided novel evidence that systemic morphine treatment can remarkably attenuate uterine stromal proliferation and angiogenesis, and thus hamper uterine receptivity, eventually leading to implantation failure. Our findings have high clinical relevance because illicit abuse of opium by women of childbearing age causes them to face an increased risk of pregnancy complications [11] [12] [13] 60] .
